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Low density lipoproteinA key event during the formation of lipid-rich foam cells during the progression of atherosclerosis is the
uptake of modiﬁed low-density lipoproteins (LDL) by macrophages in response to atherogenic mediators
in the arterial intima. In addition to scavenger receptor-dependent uptake of LDL, macropinocytosis is
known to facilitate the uptake of LDL through the constitutive and passive internalization of large quan-
tities of extracellular solute. In this study we conﬁrm the ability of macropinocytosis to facilitate the
uptake of modiﬁed LDL by human macrophages and show its modulation by TGF-b, IFN-c, IL-17A and
IL-33. Furthermore we show that the TGF-b-mediated inhibition of macropinocytosis is a Smad-2/-3-
independent process.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Atherosclerosis is a chronic inﬂammatory disease of the vascu-
lature that is governed by many risk factors including genetic pre-
disposition and diet. The disease itself is characterized by the
accumulation and retention of apolipoprotein B (apoB)-containing
lipoproteins, such as low-density lipoprotein (LDL), within the
arterial wall and the subsequent formation of foam cell-rich ﬁbro-
tic plaques that, upon rupture, result in myocardial infarction and
stroke [1]. The formation of lipid laden foam cells in the arterial in-
tima, as a result of modiﬁed LDL uptake by macrophages, repre-
sents a critical step during the progression of atherosclerosis. The
uptake of modiﬁed forms of LDL is understood to take place
through a receptor-dependent mechanism that is propagated by theincreased expression of key genes, such as scavenger receptor-A
(SR-A) and CD36, by invading macrophages [1,2]. Furthermore, this
phenotypic change is known to be tightly regulated by a multitude
of both novel and classical cytokines implicated in the control of
atherogenesis, such as interleukin (IL)-33, interferon-c (IFN-c),
and transforming growth factor-b (TGF-b) [3–5], and currently
represents the most accepted and well documented paradigm of
modiﬁed LDL uptake by macrophages.
In addition to this ‘‘classical’’ mode of lipid uptake, it has been
shown that scavenger receptor-independent processes, such as
macropinocytosis, may contribute signiﬁcantly to the uptake of
LDL by macrophages [6] and therefore drive the process of foam
cell formation. Macropinocytosis is a form of ﬂuid-phase endocyto-
sis where solute uptake is directly proportional to the volume of li-
quid internalized and the solute concentration. The process itself
involves the actin-dependent rufﬂing of the plasma membrane
and the subsequent fusion of the membrane to itself in order to
form intracellular ﬂuid ﬁlled vacuoles 0.5–5 lM in diameter
[7,8]. This process has been shown to contribute to the uptake of
oxidized (Ox-) LDL by mouse RAW264.7 macrophages [9], an
observation that may account for the appearance of LDL sized
nano-particles within macrophages present in atherosclerotic le-
sions of apoE deﬁcient mice [10]. Furthermore, macropinocytosis
has also been shown to contribute to the uptake of native and
modiﬁed forms of LDL by human peripheral blood-derived
macrophages [11], phorbol 12-myristate 13-acetate (PMA)-derived
macrophages [6] and macrophage colony-stimulating factor
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also been shown that minimally oxidized LDL (mmLDL) can induce
macropinocytosis in macrophages through a toll-like receptor
(TLR) 4/spleen tyrosine kinase (SYK) dependent mechanism and
therefore potentiate the uptake of both native and oxLDL thus con-
tributing to the progression of atherosclerosis [14,15].
Despite its clear implication during the process of foam cell for-
mation, the effect of novel and established foam cell regulators,
such as IL-33, IL-17A, IFN-c and TGF-b, on macropinocytosis re-
mains unexamined. Therefore, the objective of this study was to
conﬁrm the role of macropinocytosis on modiﬁed LDL uptake in
human macrophages and examine the effect of key cytokines
known to regulate atherosclerotic progression on this process.2. Materials and methods
2.1. Reagents and cell culture
All chemicals were purchased from Sigma–Aldrich (Poole, UK)
unless otherwise stated. Recombinant human TGF-b, IL-33, IL-
17A and IFN-c were supplied by Peprotech (London, UK). Acety-
lated LDL (AcLDL) and 1,10-dioctadecyl-3,3,30,30-tetramethyllindo-
carbocyane perchlorate (Dil)-labeled AcLDL (DiI-AcLDL) were
purchased from Intracel (Frederick, Maryland, USA).
Human monocyte-derived macrophages (HMDM) were differ-
entiated from monocytes isolated from buffy coats supplied by
the Welsh Blood service using Ficoll-Hypaque puriﬁcation de-
scribed elsewhere [3]. Ethical approval and informed consent for
each donor was granted by the Welsh Blood Service for the use
of human blood samples. Human acute monocytic leukemia cells
(THP-1) and HMDMwere maintained in complete RPMI-1640 sup-
plemented with 10% (v/v) heat-inactivated FCS, penicillin (100 U/ml),
streptomycin (100 lg/ml) and L-glutamine (2 mmol/L) (all Invitro-
gen, Paisley, UK), at 37 C in a humidiﬁed atmosphere containing
5% (v/v) CO2. THP-1 monocytes were differentiated into macro-
phages using 160 nM PMA for 24 h and this ensured high expres-
sion levels of scavenger receptors and other genes implicated in
the control of macrophage foam cell formation [16]. In all experi-
ments cells were incubated for 24 h with either 30 ng/ml of
TGF-b, 10 ng/ml of IL-33, 100 ng/ml of IL17A or 1000 U/ml of
IFN-c. THP-1 macrophages were pre-incubated with cytochala-
sin-D for 1 h prior to the addition of AcLDL, DiI-AcLDL or lucifer
yellow (LY) dipotassium salt and cytokines. Cytokines and cytocha-
lasin-D were reconstituted in PBS/0.1% bovine serum albumin
(BSA) or DMSO respectively that were subsequently used as a
vehicle controls.
2.2. DiI-AcLDL and lucifer yellow uptake assays
Cells were incubated for 24 h with DiI-AcLDL (10 lg/ml) or LY
(100 lg/ml) in RPMI-1640 containing 0.2% (v/v) fatty-acid free
BSA (Sigma–Aldrich) at 37 C. The concentration of LY reﬂects that
commonly used in the literature [17]. DiI-AcLDL and LY uptake
were analyzed by ﬂow cytometry on a FACS Canto (BD Biosciences,
Oxford, UK) ﬂow cytometer with at least 10,000 events acquired
for each sample. DiI-AcLDL and LY uptake is represented as a per-
centage with the vehicle-treated control indicated as 100%.
2.3. Real-time quantitative PCR
RNA extraction, reverse transcription and real-time quantitative
PCR analysis was performed as described elsewhere [3]. Oligonu-
cleotides speciﬁc for 60S ribosomal protein L13a (RPL13A) (for-
ward 50-CCTGGAGGAGAAGAGGAAAGAGA-30, reverse 50-TTGAG
GACCTCTGTGTATTTGTCAA-30), CD36 (forward 50-GAGAACTGTTATGGGGCTAT-30, reverse 50-TTCAACTGGAGAGGCAAAGG-30) [18]
and SR-A (forward 50-CCAGGGACATGGAATGCAA-30, reverse 50-CC
AGTGGGACCTCGATCTCC-30) [18] were purchased from Sigma Al-
drich (Poole, UK). Fold changes in expression were calculated using
2(DCt1  DCt2), where DCt represents the difference between the
threshold cycle (CT) for each target gene and RPL13A mRNA tran-
script levels. Melting curve analysis was performed on each primer
set to conﬁrm ampliﬁcation of a single product and all amplicons
were sequenced to ensure reaction speciﬁcity (data not shown).
2.4. Adenoviral infection of THP-1
Adenovirus encoding shRNA against Smad-2, Smad-3 and GAP-
DH were prepared as previously described [19]. THP-1 monocytes
were infected with RAd-GAPDH shRNA or RAd-Smad-2 shRNA or
RAd-Smad-3 shRNA at a multiplicity of infection (MOI) of 100 for
each virus in 0.5 ml RPMI-1640 medium for 2.5 h at 37 C (rock-
ing) prior to addition of 1 ml of RPMI-1640 medium (including
160 nM PMA to induce differentiation into macrophages) and
incubation for a further 72 h. An MOI of 100 was sufﬁcient to in-
fect >98% THP-1 cells as measured by ﬂow cytometry following
infection with a GFP-expressing recombinant adenovirus (data
not shown).
2.5. Statistical analysis
All data are presented as mean [±standard deviation (SD)] on
the assigned number of independent experiments or, in experi-
ments involving HMDM, experiments performed using samples
from different donors. For single comparisons, values for p were
calculated using the Student’s t-test. For multiple comparisons,
values of p were calculated using Welch’s robust test of equality
of means followed by Games–Howell post hoc analysis. Values of
p were considered signiﬁcant below 0.05.3. Results
3.1. Cytochalasin-D inhibits the uptake of LY and AcLDL in human
macrophages
The PMA differentiated THP-1 model is commonly used to
delineate human macrophage cellular functions associated with
atherosclerosis due to their conserved responses with primary
HMDM and in vivo data [3,4,20]. This cellular system was therefore
employed to examine the potential contribution of macropinocyto-
sis during foam cell formation. In light of this we ﬁrst examined the
effect of the established macropinocytosis (not micropinocytosis
[11]) inhibitor, cytochalasin-D, on the uptake of LY, a ﬂuorescent
dye commonly used to monitor macropinocytosis [7,21], by mono-
cyte derived THP-1 macrophages. As shown in Fig. 1, cytochalasin-
D, a cell permeable myotoxin that inhibits macropinocytosis
through the de-polymerization of actin ﬁlaments and tubulin
microtubules [11,12], attenuates the uptake of LY by approxi-
mately 70% (at 2.5 lg/ml) when compared to the vehicle control
treated cells.
Next, in order to further substantiate the existing evidence sug-
gesting a role for macropinocytosis in foam cell formation [7,12],
we examined the effect of cytochalasin-D (at the concentration de-
ﬁned above) on the uptake of DiI-AcLDL, a form of LDL used exten-
sively during in vitro foam cell formation assays due to its
substantial intracellular accumulation [22]. As shown in Fig. 2A,
cytochalasin-D signiﬁcantly inhibited the uptake of AcLDL by
THP-1 macrophages by approximately 37%, an observation that
was also conserved in HMDM (Fig. 2B). This response was con-
ﬁrmed by an observed reduction in the intracellular cholesterol
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Fig. 1. Cytochalasin-D inhibits LY uptake in THP-1 macrophages. LY uptake was
measured in THP-1 macrophages in response to 24 h incubation with varying
concentrations of cytochalasin-D (n = 3). DMSO was used as a vehicle control. Data
represents the mean ± SD. Statistical analysis was performed using Welch’s test of
equality of means with Games–Howell post hoc analysis, P < 0.001.
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Fig. 2. Cytochalasin-D inhibits AcLDL uptake in human macrophages. Dil-AcLDL
uptake was measured in (A) THP-1 macrophages or (B) HMDM in response to 24 h
incubation with cytochalasin-D (2.5 lg/ml, n = 3). DMSO was used as a vehicle
control in all experiments. Data represents the mean ± SD. Statistical analysis was
performed using the Student’s t-test, P < 0.001.
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Fig. 3. Cytochalasin-D inhibits LDL uptake through a scavenger receptor-indepen-
dent mechanism. The relative CD36 and SR-A mRNA expression was determined in
THP-1 macrophages incubated with Cytochalasin-D (2.5 lg/ml, n = 3). Gene-speciﬁc
mRNA expression levels were calculated using the comparative Ct method and
normalized to RPL13A levels with vehicle treated cells given an arbitrary value of 1.
DMSO was used as a vehicle control. Data represents the mean ± SD. Statistical
analysis was performed using the Student’s t-test, P < 0.05.
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plementary Fig. 1).
The uptake of AcLDL is principally regulated by cell surface
receptors that are known to facilitate the internalization of AcLDL,
as well as other forms of modiﬁed-LDL, during foam cell formation
[1]. Numerous studies have used cytochalasin-D in order to specif-
ically examine the impact of macropinocytosis, and not receptor-
mediated endocytosis, on LDL uptake [9,11,12]. Nevertheless, in order
to conﬁrm the speciﬁcity of the inhibitor for macropinocytosis we
next examined the expression of CD36 and SR-A mRNA in response
to cytochalasin-D treatment. Both CD36 and SR-A are involved in
receptor-mediated uptake of modiﬁed LDL. As shown in Fig. 3, both
CD36 and SR-A mRNA expression were signiﬁcantly increased, and
not decreased, in response to cytochalasin-D when compared to
the vehicle control.3.2. Macropinocytosis contributes to the cytokine-mediated regulation
of foam cell formation
A plethora of research focusing on atherogenic cytokines, such
as IFN-c, IL-33, IL-17A and TGF-b, has highlighted their ability to
modulate macrophage foam cell formation through scavenger
receptor-dependent mechanisms [3–5] although their effect on
macropinocytosis remains undetermined. To this end, we exam-
ined the effect of these cytokines on the uptake of LY by THP-1
macrophages. As shown in Fig. 4, IFN-c, IL-33 and TGF-b signiﬁ-
cantly inhibited LY uptake when compared to the vehicle treated
control cells. Conversely, IL-17A signiﬁcantly increased LY uptake
when compared to the vehicle treated control cells. The concentra-
tions of cytokines used in these experiments reﬂect pre-deﬁned
optimal levels for LY uptake (Supplementary Fig. 2) or, in the case
of TGF-b, a clinically relevant concentration that has been previ-
ously shown to reduce modiﬁed LDL uptake in our system [5,19].
The signaling pathways underlying the cytokine-mediated
regulation of receptor-dependent foam cell formation are well-
deﬁned [3–5,23]. For example, a recent study by our group has
shown that the Smad signal transduction pathway is responsible
for the TGF-b-mediated inhibition of AcLDL uptake by THP-1
macrophages [19]. Therefore, in order to determine if a similar
pathway plays a role in the TGF-b-mediated inhibition of macr-
opinocytosis, we examined the effect of TGF-b on LY uptake in
our previously validated adenovirus-mediated Smad deﬁcient
in vitro macrophage model [19]. As shown in Fig. 5, adenoviral
administration of shRNA’s speciﬁc for Smad-2 (RAd-Smad-2
shRNA), Smad-3 (RAd-Smad-3 shRNA) or both (RAd-Smad-2/3
shRNA) failed to abolish the statistically signiﬁcant reduction in
LY uptake observed between untreated and TGF-b treated GAPDH
shRNA (RAd-GAPDH shRNA) infected cells.4. Discussion
Complete understanding of the mechanisms by which LDL is
internalized by macrophages during inﬂammation is fundamental
to the progression of atherosclerotic research. To date, receptor-
mediated endocytosis represents the best-understood mechanism
of LDL uptake: however, it has emerged that macropinocytosis
can signiﬁcantly contribute to the process of foam cell formation
[6,9,11,12]. In this report we conﬁrm that modiﬁed LDL can indeed
be internalised by human macrophages through a potential receptor-
independent mechanism as signiﬁcant reductions in AcLDL
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Fig. 4. Differential regulation of LY uptake in THP-1 macrophages by cytokines. LY uptake was measured in THP-1 macrophages in response to 24 h incubation with IL-33
(10 ng/ml, n = 5), TGF-b (30 ng/ml, n = 4), IL-17A (100 ng/ml, n = 3) or IFN-c (1000 U/ml, n = 4). PBS/0.1% BSA was used as a vehicle control in all experiments. Data represents
the mean ± SD. Statistical analysis was performed using the Student’s t-test, P < 0.05; P < 0.01; P < 0.001.
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Fig. 5. TGF-b inhibits LY uptake by THP-1 macrophages through a Smad-indepen-
dent mechanism. LY uptake was measured in THP-1 macrophages following
infection with RAd-GAPDH shRNA or RAd-Smad-2 shRNA or RAd-Smad-3 shRNA or
RAd-Smad-2 shRNA and RAd-Smad-3 shRNA together in the presence (empty bars)
or absence (ﬁlled bars) of 24 h TGF-b (30 ng/ml) stimulation (n = 4). PBS/0.1% BSA
was used as a vehicle control. Data represents the mean ± SD. Statistical analysis
was performed using the Student’s t-test, P < 0.01; P < 0.001.
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in response to cytochalasin-D treatment in both THP-1 macro-
phages and HMDM (Fig. 2 and Supplementary Fig. 1). Cytochala-
sins have been routinely used to speciﬁcally inhibit
macropinocytosis in many studies and its inhibition of lipoprotein
uptake has now been conﬁrmed in various monocyte-derived mac-
rophage lineages [9,11,12]. Despite this, we could not eliminate the
possibility that our observed changes in AcLDL uptake were the re-
sult of inhibition of receptor-mediated LDL uptake by cytochalasin-
D. Subsequently, we were able to show that the transcript levels of
two well-established markers of receptor-mediated modiﬁed LDL
uptake, namely SR-A and CD36 [3,24], are not decreased by cyto-
chalasin-D treatment. Considering that previous work by our group
has consistently shown a direct correlation between transcripts
levels and protein expression of CD36 and SR-A in our system
[3,19], these data suggest that macropinocytosis is likely to be
the mechanism responsible for our observed changes in AcLDL
uptake and intracellular cholesterol content. Interestingly, theincreased expression of SR-A and CD36 mRNA observed in our
study may indicate the existence of a compensatory mechanism
employed by the macrophage to maintain modiﬁed LDL uptake
and cholesterol levels in the absence of the macropinocytosis path-
way. Similar compensatory mechanisms can be seen in other sys-
tems such as during the regulation of calcium transport by plasma
membrane calcium ATPase 1b in the intestine of Calbindin-D9k
knockout mice and the increased expression of b1-Adrenorecep-
tors to modulate murine gastrointestinal tissue relaxation in the
absence of the b3-Adrenoreceptor [25,26].
It is now becoming apparent that macropinocytosis is not a
completely constitutive process and is subject to modulation by
various mediators of atherosclerosis [14]. For example, recent
studies by our own group have demonstrated its inhibition by
the athero-protective long chain n-3 polyunsaturated fatty acids
[27] such as eicosapentaenoic acid and docosahexaenoic acid
which serves to further deﬁne the contribution of macropinocyto-
sis during foam cell formation. Similarly, our current study shows
that IL-33 and IL-17A, two cytokines whose roles in atherogenesis
have been recently identiﬁed [3,28], are able to modulate LY up-
take by THP-1 macrophages (Fig. 4) in a manner consistent with
their previously deﬁned atherogenic properties. IL-33, an anti-
atherogenic cytokine known to reduce foam cell formation in
human macrophages [3], signiﬁcantly reduces the amount of LY
internalised by human macrophages while IL-17A, mainly a
pro-athergenic cytokine that has been shown in some studies to
promote the progression of lesion development in apoE knockout
mice [28], is able to induce LY uptake. Furthermore, our study also
shows that IFN-c can signiﬁcantly reduce the uptake of LY by THP-
1 macrophages (Fig. 4) suggesting an anti-atherogenic role for IFN-
c during foam cell formation. In light of both pro- and anti-athero-
genic roles of IFN-c, at least in vitro [29], it seems plausible to sug-
gest that the magnitude of IFN-c induced receptor-dependent LDL
uptake seen in various studies [29] is sufﬁcient to mask its inhibi-
tory effect on macropinocytosis resulting in a net foam cell stimu-
latory effect. However, it is possible that inhibition of
macropinocytosis represents another anti-atherogenic action of
IFN-c in vitro.
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TGF-b, can also inhibit the uptake of LY by THP-1 macrophages
(Fig. 4), which is consistent with a plethora of existing evidence
demonstrating the athero-protective properties of this cytokine
[30]. Interestingly, as seen in our previously established virally
mediated Smad-deﬁcient system (Fig. 5), this process was found
to occur independently of the Smad signal transduction pathway,
unlike the Smad-dependent TGF-b-mediated inhibition of
receptor-dependent AcLDL uptake [19], suggesting that macropin-
ocytosis and receptor-mediated endocytosis may be regulated by
distinct signaling pathways. Although the mechanisms underlying
the TGF-b-mediated inhibition of macropinocytosis remains un-
elucidated, TGF-b is known to signal throughmany other signalling
molecules such as c-Jun N-terminal kinase, p38 kinase and casein
kinase 2 [30], which may therefore represent promising avenues
for future macropinocytotic research.
4.1. Conclusion
In summary, we have conﬁrmed that macropinocytosis plays a
signiﬁcant role during the process of foam cell formation by facil-
itating the internalisation of AcLDL in human macrophages. Fur-
thermore we demonstrate, for the ﬁrst time, that the process of
macropinocytosis is modulated by key cytokines implicated in ath-
erosclerosis such as IFN-c, TGF-b, IL-33 and IL-17A in a manner
mostly consistent with their ability to promote or hinder foam cell
formation and suggest that TGF-b inhibits macropinocytosis
through a Smad-independent pathway. Together, these data
clearly demonstrate the importance of macropinocytosis during
foam cell formation and highlight it as a potential target for ther-
apeutic intervention.
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